Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness The ESCAPE Trial

CONTEXT Pulmonary artery catheters (PACs) have been used to guide therapy in multiple settings, but recent studies have raised concerns that PACs may lead to increased mortality in hospitalized patients. OBJECTIVE To determine whether PAC use is safe and improves clinical outcomes in patients hospitalized with severe symptomatic and recurrent heart failure. DESIGN, SETTING, AND PARTICIPANTS The Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) was a randomized controlled trial of 433 patients at 26 sites conducted from January 18, 2000, to November 17, 2003. Patients were assigned to receive therapy guided by clinical assessment and a PAC or clinical assessment alone. The target in both groups was resolution of clinical congestion, with additional PAC targets of a pulmonary capillary wedge pressure of 15 mm Hg and a right atrial pressure of 8 mm Hg. Medications were not specified, but inotrope use was explicitly discouraged. MAIN OUTCOME MEASURES The primary end point was days alive out of the hospital during the first 6 months, with secondary end points of exercise, quality of life, biochemical, and echocardiographic changes. RESULTS Severity of illness was reflected by the following values: average left ventricular ejection fraction, 19%; systolic blood pressure, 106 mm Hg; sodium level, 137 mEq/L; urea nitrogen, 35 mg/dL (12.40 mmol/L); and creatinine, 1.5 mg/dL (132.6 micromol/L). Therapy in both groups led to substantial reduction in symptoms, jugular venous pressure, and edema. Use of the PAC did not significantly affect the primary end point of days alive and out of the hospital during the first 6 months (133 days vs 135 days; hazard ratio [HR], 1.00 [95% confidence interval {CI}, 0.82-1.21]; P = .99), mortality (43 patients [10%] vs 38 patients [9%]; odds ratio [OR], 1.26 [95% CI, 0.78-2.03]; P = .35), or the number of days hospitalized (8.7 vs 8.3; HR, 1.04 [95% CI, 0.86-1.27]; P = .67). In-hospital adverse events were more common among patients in the PAC group (47 [21.9%] vs 25 [11.5%]; P = .04). There were no deaths related to PAC use, and no difference for in-hospital plus 30-day mortality (10 [4.7%] vs 11 [5.0%]; OR, 0.97 [95% CI, 0.38-2.22]; P = .97). Exercise and quality of life end points improved in both groups with a trend toward greater improvement with the PAC, which reached significance for the time trade-off at all time points after randomization. CONCLUSIONS Therapy to reduce volume overload during hospitalization for heart failure led to marked improvement in signs and symptoms of elevated filling pressures with or without the PAC. Addition of the PAC to careful clinical assessment increased anticipated adverse events, but did not affect overall mortality and hospitalization. Future trials should test noninvasive assessments with specific treatment strategies that could be used to better tailor therapy for both survival time and survival quality as valued by patients.

[1]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[2]  G. Jennings,et al.  Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. , 1994, Journal of the American College of Cardiology.

[3]  K. Shine,et al.  Vasodilator Therapy for Chronic Left Ventricular Failure , 1976, Circulation.

[4]  K. Aaronson,et al.  Short-term Risk of Death After Treatment With Nesiritide for Decompensated Heart Failure: A Pooled Analysis of Randomized Controlled Trials , 2005 .

[5]  S. Solomon,et al.  The mechanism of decrease in dynamic mitral regurgitation during heart failure treatment: importance of reduction in the regurgitant orifice size. , 1998, Journal of the American College of Cardiology.

[6]  G. Biasi,et al.  Impact of perioperative haemodynamic monitoring on cardiac morbidity after major vascular surgery in low risk patients. A randomised pilot trial. , 2002, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[7]  M. Davidian,et al.  Semiparametric Estimation of Treatment Effect in a Pretest-Posttest Study with Missing Data. , 2005, Statistical science : a review journal of the Institute of Mathematical Statistics.

[8]  V. Hasselblad,et al.  Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): design and rationale. , 2001, American heart journal.

[9]  F. Cerra,et al.  Preoperative optimization of cardiovascular hemodynamics improves outcome in peripheral vascular surgery. A prospective, randomized clinical trial. , 1991, Annals of surgery.

[10]  T. Rector,et al.  Use of the Living With Heart Failure questionnaire to ascertain patients' perspectives on improvement in quality of life versus risk of drug-induced death. , 1995, Journal of cardiac failure.

[11]  L. Stevenson,et al.  Preferences for quality of life or survival expressed by patients with heart failure. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  William A. Knaus,et al.  The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. , 1996, Journal of the American Medical Association (JAMA).

[13]  W. Abraham,et al.  Patient preferences for heart failure treatment: utilities are valid measures of health-related quality of life in heart failure. , 1999, Journal of cardiac failure.

[14]  Q. Li,et al.  Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. , 1998, The Journal of clinical investigation.

[15]  L. Stevenson,et al.  Exercise capacity for survivors of cardiac transplantation or sustained medical therapy for stable heart failure. , 1990, Circulation.

[16]  M. Luu,et al.  Effect of direct vasodilation with hydralazine versus angiotensin-converting enzyme inhibition with captopril on mortality in advanced heart failure: the Hy-C trial. , 1992, Journal of the American College of Cardiology.

[17]  G. Torrance Measurement of health state utilities for economic appraisal. , 1986, Journal of health economics.

[18]  G. Fonarow,et al.  Improvement in exercise capacity of candidates awaiting heart transplantation. , 1995, Journal of the American College of Cardiology.

[19]  W John Boscardin,et al.  Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. , 2005, JAMA.

[20]  C. Lang,et al.  Treatment of subclinical fluid retention in patients with symptomatic heart failure: effect on exercise performance. , 1997, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[21]  U. Goldbourt,et al.  Use of pulmonary artery catheters in patients with acute myocardial infarction. Analysis of experience in 5,841 patients in the SPRINT Registry. SPRINT Study Group. , 1990, Chest.

[22]  M. Schwaiger,et al.  Afterload reduction with vasodilators and diuretics decreases mitral regurgitation during upright exercise in advanced heart failure. , 1990, Journal of the American College of Cardiology.

[23]  R. Brant,et al.  A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. , 2003, The New England journal of medicine.

[24]  William J. Rogers,et al.  Prediction of Mortality and Morbidity With a 6-Minute Walk Test in Patients With Left Ventricular Dysfunction , 1993 .

[25]  G. Fonarow,et al.  Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. , 1997, Journal of the American College of Cardiology.

[26]  G. Francis,et al.  Medical management of terminal cardiomyopathy , 1982 .

[27]  R. Bone,et al.  Is it time to pull the pulmonary artery catheter? , 1996, JAMA.

[28]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[29]  C. O'connor,et al.  Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. , 2004, American heart journal.

[30]  Milton Packer,et al.  Cardiac resynchronization in chronic heart failure. , 2002, The New England journal of medicine.

[31]  L. Stevenson,et al.  Maintenance of cardiac output with normal filling pressures in patients with dilated heart failure. , 1986, Circulation.

[32]  Peter C. Austin,et al.  Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. , 2003, JAMA.

[33]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[34]  M. Singer,et al.  Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care ( PAC-Man ) : a randomised controlled trial , 2022 .

[35]  M. Woo,et al.  Sustained reduction in valvular regurgitation and atrial volumes with tailored vasodilator therapy in advanced congestive heart failure secondary to dilated (ischemic or idiopathic) cardiomyopathy. , 1991, The American journal of cardiology.

[36]  L. Stevenson,et al.  Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. , 1999, American heart journal.

[37]  Y. Yazaki,et al.  Mechanical loading stimulates cell hypertrophy and specific gene expression in cultured rat cardiac myocytes. Possible role of protein kinase C activation. , 1991, The Journal of biological chemistry.

[38]  William T. Abraham,et al.  Risk stratification for in-hospital mortality in acutely decompensated heart failure. Classification and regression tree analysis , 2005 .

[39]  J. Alpert,et al.  A community-wide assessment of the use of pulmonary artery catheters in patients with acute myocardial infarction. , 1987, Chest.

[40]  B. Pitt,et al.  The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure , 2000 .

[41]  G. Fonarow,et al.  Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. , 2000, American heart journal.

[42]  J. Schwartz,et al.  Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. , 1996, Circulation.

[43]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[44]  G. Fonarow,et al.  Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. , 1997, Circulation.

[45]  G. Fonarow,et al.  Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[46]  J. Bender,et al.  Routine pulmonary artery catheterization does not reduce morbidity and mortality of elective vascular surgery: results of a prospective, randomized trial. , 1997, Annals of surgery.

[47]  R. J. Valentine,et al.  Effectiveness of pulmonary artery catheters in aortic surgery: a randomized trial. , 1998, Journal of vascular surgery.

[48]  L. Stevenson,et al.  Efficacy of medical therapy tailored for severe congestive heart failure in patients transferred for urgent cardiac transplantation. , 1989, The American journal of cardiology.

[49]  M. Luu,et al.  Importance of hemodynamic response to therapy in predicting survival with ejection fraction less than or equal to 20% secondary to ischemic or nonischemic dilated cardiomyopathy. , 1990, The American journal of cardiology.

[50]  C Larizza,et al.  Predictors of prognosis in patients awaiting heart transplantation. , 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[51]  Trottier Sj,et al.  Physicians' attitudes toward and knowledge of the pulmonary artery catheter: Society of Critical Care Medicine membership survey. , 1997 .